Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer

References

• Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001; 81: 398–403
   PubMed Web of Science ®Google Scholar
• Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991; 9: 1138–50
   PubMed Web of Science ®Google Scholar
• Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 1994; 53: 27–32
   PubMed Web of Science ®Google Scholar
• Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer. 2000; 83: 1488–94
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Von Minckwitz G, Kuhn W, Schmid H, Costa S, Goerttler K, et al. Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma. Int J Gynecol Cancer. 1995; 5: 49–55
   PubMed Web of Science ®Google Scholar
• Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002; 100: 59–64
   PubMed Web of Science ®Google Scholar
• Pittendrigh CS. Temporal organization: reflections of a Darwinian clock-watcher. Annu Rev Physiol. 1993; 55: 16–54
   PubMed Web of Science ®Google Scholar
• You S, Wood PA, Xiong Y, Kobayashi M, Du-Quiton J, Hrushesky WJ. Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat. 2005; 91: 47–60
   PubMed Web of Science ®Google Scholar
• Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006; 15: 271–7
   PubMed Web of Science ®Google Scholar
• Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, et al. Mutagenesis and mapping of a mouse gene, clock, essential for circadian behavior. Science. 1994; 264: 719–25
   PubMed Web of Science ®Google Scholar
• King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, et al. Positional cloning of the mouse circadian clock gene. Cell. 1997; 89: 641–53
   PubMed Web of Science ®Google Scholar
• Tei H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M, et al. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature. 1997; 389: 512–6
   PubMed Web of Science ®Google Scholar
• Sun ZS, Albrecht U, Zhuchenko O, Bailey J, Eichele G, Lee CC. RIGUI, a putative mammalian ortholog of the Drosophila period gene. Cell. 1997; 90: 1003–11
   PubMed Web of Science ®Google Scholar
• Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science. 1998; 280: 1564–9
   PubMed Web of Science ®Google Scholar
• Sangoram AM, Saez L, Antoch MP, Gekakis N, Staknis D, Whiteley A, et al. Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998; 21: 1101–13
   PubMed Web of Science ®Google Scholar
• Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001; 93: 1557–62
   PubMed Web of Science ®Google Scholar
• Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst. 2001; 93: 1563–8
   PubMed Web of Science ®Google Scholar
• Sahar S, Sassone-Corsi P. Circadian clock and breast cancer: a molecular link. Cell Cycle. 2007; 6: 1329–31
   PubMed Web of Science ®Google Scholar
• Cai W, Rambaud J, Teboul M, Masse I, Benoit G, Gustafsson JA, et al. Expression levels of estrogen receptor beta are modelated by components of the molecular clock. Mol Cell Biol. 2008; 28: 784–93
   PubMed Web of Science ®Google Scholar
• Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. 2007; 26: 7916–20
   Google Scholar
• Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology. 2005; 16: 254–8
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Maestroni G, Cardinali D, Esquifino A, Perumal SP, Miller S. Melatonin, immune function and aging. Immun Ageing. 2005; 2: 17
   PubMedGoogle Scholar
• Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000; 92: 994–1000
   PubMed Web of Science ®Google Scholar
• Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000; 6: 3038–45
   PubMed Web of Science ®Google Scholar
• Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer. 1997; 70: 241–7
   PubMed Web of Science ®Google Scholar
• Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003; 3: 350–61
   PubMed Web of Science ®Google Scholar
• Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417: 78–83
   PubMed Web of Science ®Google Scholar
• Shih HC, Choo KB, Chang TJ, Yang MY, Shih MC, Yeh KT, et al. Disturbance of circadian gene expression in endometrial cancer: detection by real-time quantitative RT-PCR. Oncol Rep. 2005; 14: 1533–8
   PubMed Web of Science ®Google Scholar
• Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26: 1241–6
   PubMed Web of Science ®Google Scholar
• Hrushesky WJ. Circadian timing of cancer chemotherapy. Science. 1985; 228: 73–5
   PubMed Web of Science ®Google Scholar
• Hrushesky WJ, Bjarnason GA. Circadian cancer therapy. J Clin Oncol. 1993; 11: 1403–17
   PubMed Web of Science ®Google Scholar
• Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994; 86: 1608–17
   PubMed Web of Science ®Google Scholar
• Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997; 350: 681–6
   PubMed Web of Science ®Google Scholar
• Klevecz RR, Shymko RM, Blumenfeld D, Braly PS. Circadian gating of S phase in human ovarian cancer. Cancer Res. 1987; 47: 6267–71
   PubMed Web of Science ®Google Scholar
• Klevecz RR, Braly PS. Circadian and ultradian rhythms of proliferation in human ovarian cancer. Chronobiol Int. 1987; 4: 513–23
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features – problems involved in the architectural grading system. Gynecol Oncol. 1998; 70: 2–12
   PubMed Web of Science ®Google Scholar
• Wang YQ, Hua H, Zhu B, Yin HH, Liu YY, Yang CL, et al. [The influence of circadian gene mPeriod2 on Lewis cancer cell]. Space Med Med Eng (Beijing) 2005; 18: 222–3
   PubMedGoogle Scholar
• Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94: 690–7
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111: 41–50
   PubMed Web of Science ®Google Scholar
• Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005; 25: 3109–16
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003; 302: 255–9
   PubMed Web of Science ®Google Scholar
• Gauger MA, Sancar A. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 2005; 65: 6828–34
   PubMed Web of Science ®Google Scholar
• Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006; 15(2)R271–7
   PubMed Web of Science ®Google Scholar
• Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004; 22: 1040–4
   PubMed Web of Science ®Google Scholar
• Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A. 2005; 102: 3407–12
   PubMed Web of Science ®Google Scholar